Apixaban in Japanese patients with cancer-associated venous thromboembolism: a multi-center phase II trial.

Yoshinori ImamuraKazunori OtsuiKenta MoriKoichi KitagawaHideaki OkadaAkito HataHidetoshi HayashiTaku NoseShinya OhataYoshiharu MiyataYohei FunakoshiMasanori ToyodaKimikazu YakushijinNaomi KiyotaHiroshi MatsuokaHironobu Minami

Published in: International journal of hematology (2022)

This study demonstrated the excessive bleeding risk of apixaban at the standard dose in Japanese patients with cancer-associated VTE.

Keyphrases

venous thromboembolism
direct oral anticoagulants
atrial fibrillation
open label
randomized controlled trial
weight gain
physical activity
body mass index